eli lilly glp 1 market share GLP-1 Analogues Size to Hit USD 1,062.90 Billion by 2035 Eli Lilly Shows Why the

Meurot C et al

Clinical trials have shown that semaglutide, when prescribed and monitored appropriately, may support significant weight loss

Before Starting GLP-1 Assess the 4 Drivers of Health Metabolism, Hormones, Inflammation, Recovery Identify which internal drivers are contributing to weight gain Establish baseline metabolic and hormonal markers Set realistic expectations for the medication AND the work that needs to happen alongside it During GLP-1 Treatment Use the appetite window to build sustainable eating habits (not just eat less) Incorporate strength training to preserve muscle mass Address underlying metabolic and hormonal factors in parallel Support gut health and reduce inflammation Improve sleep and manage stress Monitor metabolic markers to track internal improvement, not just weight Transitioning Off GLP-1 Gradual dose reduction rather than abrupt stopping Metabolic and hormonal markers re-assessed Sustainable habits tested without medication support Continued monitoring and adjustment The goal is to use the medication as a bridge creating a window of reduced appetite and improved insulin sensitivity while the real work of changing the internal environment happens underneath

Tirzepatide works on two hormone pathways instead of one, which may lead to stronger appetite suppression for some patients